235 related articles for article (PubMed ID: 37882361)
41. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
42. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
[TBL] [Abstract][Full Text] [Related]
43. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
[TBL] [Abstract][Full Text] [Related]
44. Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol; 2022 Dec; 97(12):1638-1651. PubMed ID: 36255040
[TBL] [Abstract][Full Text] [Related]
45. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherril B; Ruiz-Soto R; Kaye JA; Hamadani M
J Oncol Pharm Pract; 2016 Oct; 22(5):666-78. PubMed ID: 26320127
[TBL] [Abstract][Full Text] [Related]
46. Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
[TBL] [Abstract][Full Text] [Related]
47. Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.
Bachy E; Rufibach K; Parreira J; Launonen A; Nielsen T; Hackshaw A
Adv Ther; 2021 Jul; 38(7):3489-3505. PubMed ID: 34041708
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.
Kanters S; Ball G; Kahl B; Wiesinger A; Limbrick-Oldfield EH; Sudhindra A; Snider JT; Patel AR
BMC Cancer; 2023 Jan; 23(1):74. PubMed ID: 36690960
[TBL] [Abstract][Full Text] [Related]
49. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
50. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
51. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G; Bazarbachi A; El-Cheikh J
Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
[TBL] [Abstract][Full Text] [Related]
52. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Nuvvula S; Dahiya S; Patel SA
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
[TBL] [Abstract][Full Text] [Related]
53. Divergent paths: management of early relapsed follicular lymphoma.
Takiar R; Karimi Y; Phillips TJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):666-675. PubMed ID: 36485106
[TBL] [Abstract][Full Text] [Related]
54. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
55. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
[TBL] [Abstract][Full Text] [Related]
56. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.
Ollila TA; Olszewski AJ
Cancer Manag Res; 2021; 13():3935-3952. PubMed ID: 34017197
[TBL] [Abstract][Full Text] [Related]
57. Top advances in lymphoma for 2021.
Patel DA; Kahl BS
Cancer; 2022 Dec; 128(23):4047-4051. PubMed ID: 36201139
[TBL] [Abstract][Full Text] [Related]
58. [Follicular lymphoma].
Tomita N
Nihon Rinsho; 2014 Mar; 72(3):488-92. PubMed ID: 24724409
[TBL] [Abstract][Full Text] [Related]
59. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Merryman RW; Redd RA; Freedman AS; Ahn IE; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen ED; Kim AI; LaCasce AS; Ng S; Odejide OO; Parry EM; Isufi I; Kline J; Cohen JB; Mehta-Shah N; Bartlett NL; Mei M; Kuntz TM; Wolff J; Rodig SJ; Armand P; Jacobson CA
Ann Hematol; 2024 Jan; 103(1):185-198. PubMed ID: 37851072
[TBL] [Abstract][Full Text] [Related]
60. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]